Seqens Seqens

X
[{"orgOrder":0,"company":"myTomorrows","sponsor":"AiCuris Anti-infective Cures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AiCuris collaborates with myTomorrows","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by myTomorrows

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.

            Lead Product(s): Pritelivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: AiCuris Anti-infective Cures

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 12, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY